Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R

References

• EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
   PubMed Web of Science ®Google Scholar
• Gordon PH. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis. 2013;04:295–310.
   Google Scholar
• Rocha JA, Reis C, Simoes F, Fonseca J, Mendes Ribeiro J. Diagnostic investigation and multidisciplinary management in motor neuron disease. J Neurol. 2005;252:1435–47.
   PubMed Web of Science ®Google Scholar
• Gil J, Funalot B, Verschueren A, Danel-Brunaud V, Camu W, Vandenberghe N, et al. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol. 2008;15:1245–51.
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–26.
   PubMed Web of Science ®Google Scholar
• Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration. Chest. 1993;103:508–13.
   PubMed Web of Science ®Google Scholar
• Pinto S, de Carvalho M. The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:120–3.
   PubMed Web of Science ®Google Scholar
• Bourke SC. Respiratory involvement in neuromuscular disease. Clin Med (Lond). 2014;14:72–5.
   PubMed Web of Science ®Google Scholar
• Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390–2.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4:605–18.
   PubMedGoogle Scholar
• Pinto S, de Carvalho M. Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:86–91.
   PubMed Web of Science ®Google Scholar
• Chhabra SK. Forced vital capacity, slow vital capacity, or inspiratory vital capacity: which is the best measure of vital capacity? J Asthma. 1998;35:361–5.
   PubMed Web of Science ®Google Scholar
• Caress JB, Paladenech CC. Respiratory therapy. In: Bedlack RS, Mitsumoto H, ed. Amyotrophic lateral sclerosis: a patient care guide for clinicians. New York: Demos Medical Publishing, 2013:137–50.
   Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Levy G, Thompson JL, DelBene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
   PubMed Web of Science ®Google Scholar
• Fitting JW, Paillex R, Hirt L, Aebischer P, Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol. 1999;46:887–93.
   PubMed Web of Science ®Google Scholar
• Pinto S, de Carvalho M. Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:528–33.
   PubMed Web of Science ®Google Scholar
• Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140–7.
   PubMed Web of Science ®Google Scholar
• Vandoorne E, Vrijsen B, Belge C, Testelmans D, Buyse B. Noninvasive ventilation in amyotrophic lateral sclerosis: effects on sleep quality and quality of life. Acta Clin Belg. 2016;71:389–94.
   PubMed Web of Science ®Google Scholar
• Vrijsen B, Buyse B, Belge C, Robberecht W, Van Damme P, Decramer M, et al. Noninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study. J Clin Sleep Med. 2015;11:559–66.
   PubMed Web of Science ®Google Scholar
• Burkhardt C, Neuwirth C, Sommacal A, Andersen PM, Weber M. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS One. 2017;12:e0177555.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Salachas F, Bruneteau G, Pradat PF, Lacomblez L, Gonzalez-Bermejo J, et al. Improving survival in a large French ALS center cohort. J Neurol. 2012;259:1788–92.
   PubMed Web of Science ®Google Scholar
• Leonardis L, Dolenc Grošelj L, Vidmar G. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol. 2012;19:1518–24.
   PubMed Web of Science ®Google Scholar
• Oh J, Kim JA. Information-seeking behavior and information needs in patients with amyotrophic lateral sclerosis: analyzing an online patient community. Comput Inform Nurs. 2017;35:345–51.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Levy G, Montes J, Buchsbaum R, Barsdorf AI, Battista V, et al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8:42–6.
   PubMed Web of Science ®Google Scholar
• Leigh PN, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:84–98.
   PubMed Web of Science ®Google Scholar
• Marin B, Bianchi E, Pupillo E, Lunetta C, Tremolizzo L, Logroscino G, et al. Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:77–84.
   PubMed Web of Science ®Google Scholar
• Cipolletta S, Gammino GR, Palmieri A. Illness trajectories in patients with amyotrophic lateral sclerosis: how illness progression is related to life narratives and interpersonal relationships. J Clin Nurs. 2017;26:5033–43.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME; on behalf of the NEALS Consortium. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933–5.
   PubMed Web of Science ®Google Scholar
• Voustianiouk A, Seidel G, Panchal J, Sivak M, Czaplinski A, Yen A, et al. ALSFRS and appel ALS scores: discordance with disease progression. Muscle Nerve. 2008;37:668–72.
   PubMed Web of Science ®Google Scholar
• Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11:178–80.
   PubMed Web of Science ®Google Scholar
• Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:381–5.
   PubMed Web of Science ®Google Scholar
• Vender RL, Mauger D, Walsh S, Alam S, Simmons Z. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotroph Lateral Scler. 2007;8:36–41.
   PubMed Web of Science ®Google Scholar